Vous êtes ici

Biocure Technology Inc.

Liste d'échange: 
CSE
Statut: 
Halted Pending Fundamental Change
Industrie: 
Life Sciences
Symbole: 
CURE
Indice CSE: 
Devise: 

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.

Vous êtes ici

Biocure Technology Inc. (CURE)

SEDAR Information

Information d'entreprise

Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
Canada
Téléphone
604-609-7146
Fax
N/A
Courriel
[email protected]
URL
http://www.biocuretech.com
Date d’inscription à la cote
Lundi, mai 10, 2010
Relations avec les investisseurs
n/a
Vérificateur
DMCL Chartered Professional Accountants

Capitalisation

Capitalisation: 
94000537
Réservé à l'émission: 
14510547

Company Officers

Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer

Bulletins

18/09/2023

2023-0927 - Arrêté pour un Changement Fondamental - Biocure Technology Inc. (CURE)

le 18 septembre/September 2023

Trading in the shares of Biocure Technology Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Acquisition pursuant to CSE Policy 8. This regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange, pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.